RxDoctor Payments Data

Iqbal Dhanani, MD

Psychiatry · College Park, GANPI 1972674190

Payments from drug & device makers

$9,234in general payments, 2019–2025

Across 240 payments — averaging $38.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • AbbVie$883
  • Neurocrine Biosciences, Inc.$805
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$577
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$9,12499%
  • Education$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,234 in reported general payments places this provider in the 90th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$72,366
Medicare patients
93
Services billed
787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine24$168,674
IngrezzaValbenazine Tosylate16$133,781
Invega SustennaPaliperidone Palmitate36$75,970
Abilify MaintenaAripiprazole12$34,136
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl121$17,008
Aripiprazole101$4,488
Quetiapine Fumarate264$3,593
Asenapine Maleate13$3,085
Paliperidone ErPaliperidone27$2,515
Divalproex Sodium ErDivalproex Sodium71$1,927
Hydroxyzine Pamoate206$1,871
Haloperidol66$1,101
Bupropion Hcl SrBupropion Hcl122$1,072
Duloxetine Hcl96$922
Trazodone Hcl240$892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,377$168,67424 claims
Neurocrine Biosciences, Inc.Ingrezza$805$133,78116 claims
Johnson & JohnsonInvega Sustenna$2,812$75,97036 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$1,158$34,13612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in College Park

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →